The Biden administration is considering how to expand access to possible coronavirus antiviral medicine as supply grows in the coming months, according to the Wall Street Journal, which cited a source familiar with the preparations.
According to the Journal, the administration is considering whether Paxlovid, a Pfizer Inc antiviral, may be sold commercially at retail pharmacies if it receives regulatory approval.
Molnupiravir, a Merck & Co Inc and Ridgeback Biotherapeutics LP oral tablet that is also undergoing regulatory evaluation, may be added in the government’s plan to make it available for purchase, according to the journal, which cited the source.
The United States has decided to purchase 10 million units of Pfizer’s medication and 3.1 million units of Merck’s medication. The Food and Drug Administration (FDA) in the United States is now considering petitions for the medications’ emergency use authorization.
According to Reuters, Pfizer cited its supply agreement with the US government, which was disclosed on Thursday. Merck and the US Department of Health and Human Services (HHS) did not reply to requests for comment right away.
Both treatments are seen as viable weapons in the fight against the public health crisis, with nations scurrying to obtain supply agreements following the businesses’ encouraging statistics.
According to the statement, the US government is pressuring drugmakers to accelerate manufacturing, and commercial sales may occur as the supply of the tablets rises.